Jazz Pharmaceuticals PLC Form 4 insider transactions

Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, Samantha Pearce, reports acquisition of shares through performance award vesting and a stock purchase plan, along with a disposition of shares to cover tax obligations.

Bruce C Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, sold 1,500 ordinary shares on January 2, 2025, at a price of $123.43 per share.

Renee D Gala, President & COO of Jazz Pharmaceuticals, sold 80 ordinary shares to cover tax obligations and acquired 215 shares through an employee stock purchase plan.

Jazz Pharmaceuticals CEO Bruce C. Cozadd sold 2,000 ordinary shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, sold 53 ordinary shares on December 2, 2024.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, sold 3,700 ordinary shares at an average price of $123.41 on November 8, 2024.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,000 ordinary shares at a price of $110.84 on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, sold 1,410 ordinary shares to cover tax obligations arising from vested restricted stock units.

Director Patrick Enright reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.

Director Rick Winningham reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Director Mark Smith reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares related to restricted stock units.

Director Norbert Riedel reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares, including shares sold to cover tax obligations.

Director Anne O'Riordan reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares related to restricted stock units.

Director Kenneth O'Keefe reports acquisition and disposal of Jazz Pharmaceuticals shares, including those to cover tax obligations.

Director Heather McSharry reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations.

Director Jennifer Cook of Jazz Pharmaceuticals reports acquisition and disposal of ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports acquisition of shares and restricted stock units.

Director Seamus Mulligan reports acquisition of restricted stock units in Jazz Pharmaceuticals.

Director Patrick Kennedy reports acquisition of restricted stock units and disposal of ordinary shares in Jazz Pharmaceuticals.

Director Laura Hamill reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported the sale of 163 ordinary shares on June 7, 2024.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals plc, sold 5,000 ordinary shares at an average price of $109.65 on May 3, 2024.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, disposed of 1,736 ordinary shares on April 5, 2024, to cover tax obligations arising from vesting restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sold shares of the company's ordinary stock on March 6th and 7th, 2024, to satisfy tax obligations arising from vesting restricted stock units.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the disposal of 3,622 ordinary shares to cover tax obligations arising from vesting restricted stock units on March 5, 2024.

Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports the disposal of 2,474 ordinary shares to cover tax obligations.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the disposal of 3,432 ordinary shares to cover tax obligations.

Robert Iannone, EVP, Global Head of R&D at Jazz Pharmaceuticals, disposed of shares to cover tax obligations arising from vesting restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, disposed of 22,436 ordinary shares on March 5, 2024, to satisfy tax obligations related to vesting restricted stock units.

Mary Elizabeth Henderson, SVP, Technical Operations at Jazz Pharmaceuticals, reports the acquisition of 5,178 ordinary shares and disposal of 15,941 ordinary shares on March 1, 2024.